Tadalafil

—

evidence score

hormonal

Prescription Only

CialisAdcircatadalafil daily+1 more

Tadalafil is a PDE5 (phosphodiesterase type 5) inhibitor FDA-approved for erectile dysfunction, benign prostatic hyperplasia (BPH), and pulmonary arterial hypertension. Its 36-hour half-life distinguishes it from sildenafil (Viagra, 4-5h) — allowing the "weekend pill" or daily low-dose (5mg) dosing strategies. Beyond sexual function, daily tadalafil has growing evidence for: improved exercise tolerance, reduced blood pressure, anti-inflammatory effects via cGMP pathway, potential neuroprotection, and cardiovascular benefits. At 5mg/day it is FDA-approved for both ED and BPH, and is widely used off-label as part of longevity and cardiovascular optimization protocols.

Evidence

No score yet

Safety

Unknown safety profile

Clinical Status

No formal phase listed

Research Sync

Not synced yet

Dosing

Typical

5 mg

2.5 mgRange20 mg

Frequencydaily (5mg) or as needed (10-20mg)

Set height & weight in Settings to see your dose.

Pharmacology

Half-life~17.5 hours

OnsetErectile effects within 1 hour; daily dosing steady-state in 5 days

DurationUp to 36 hours per dose; daily dosing maintains continuous effect

Routes

oral

Evidence Score

—

0 studies indexed

Scoring Factors

Volume(40%)—

Quality(30%)—

Sample Size(10%)—

Consistency(10%)—

Replication(5%)—

Recency(5%)—

Evidence Levels

AScore ≥75 with at least 1 meta-analysis and 3+ RCTs

BScore ≥50 with at least 1 RCT or meta-analysis

CScore ≥25 — observational or animal evidence only

DScore <25 — very limited or preclinical data

Plain-English Snapshot

Tadalafil is currently categorized as a hormonal compound.

Evidence scoring has not been fully computed yet, so interpret this profile as preliminary.

Safety scoring is incomplete. Start conservatively and monitor carefully.

Core mechanism

Selective PDE5 inhibitor; prevents cGMP degradation in vascular smooth muscle → eNOS-derived NO maintains vasodilation → sustained vasodilation in penile corpus cavernosum, pulmonary vasculature, prostate

Practical Context

Strongest current signals

No indexed study summaries yet.

Elevated caution signals

1 severe/high side effect flag